Inhibiting the Precipitation of Poorly Water-Soluble Drugs from Labrasol Formulations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inhibiting the Precipitation of Poorly Water-Soluble Drugs from Labrasol Formulations
The study results suggested that Pluronic F127 might be a potent inhibitor of drug precipitation for Labrasol formulations.


Pharmaceutical Technology
Volume 35, Issue 6, pp. 50-54

References

1. R. Lipper, Modern Drug Discov. 2 (1), 255–260 (1999).

2. C.A. Lipinski, American Pharm. Rev. (Fall), 582–585 (2002).

3. C.A. Lipinski, J. Pharmacol. Toxicol. Methods 44 (1), 235–249 (2001).

4. R.A. Prentis, Y. Lis, and S.R. Walker, Br. J. Clin. Pharmacol. 25 (3), 387–396 (1988).

5. S.H. Yalkowsky, Solubility and Solubilization in Aqueous Media, S.H. Yalkowsky, Ed. (Oxford Univeristy Press, New York, 2000).

6. R.G. Strickley, Pharm. Res. 21 (2), 201–230 (2004).

7. P.C. Sheen et al., Int. J. Pharm. 118 (2), 221–227 (1995).

8. S. Fernandez et al., Pharm. Res. 26 (8), 1901–1910 (2009).

9. W.G. Dai, Int. J. Pharm. 393 (1–2), 1–16 (2010).

10. W.G. Dai et al., J. Pharm. Sci. 96 (11), 2957–2969 (2007).

11. B.A. Hoener and L.Z. Benet, "Factors Influencing Drug Absorption and Drug Availability," in Drugs and the Pharmaceutical Sciences, G.S. Banker and C. Rhodes, Eds. (Informa Healthcare, New York, 4th ed., 2002), pp. 93–117.

12. S. Barakat Nahla, J. Pharm. Pharmacol. 62 (2), 173–180 (2010).

13. T.R. Kommuru et al., Int. J. Pharm. 212 (2), 233–246 (2001).

14. H.J. Kim et al, Drug Dev. Ind. Pharm. 26 (5), 523–529 (2000).

15. G. Venkatesh et al., Drug Dev. Ind. Pharm. 36 (6), 735–745 (2010).

16. W.G. Dai et al., Int. J. Pharm. 336 (1), 1–11 (2007).

17. W.G. Dai et al., Adv. Drug Deliv. Rev. 60 (6), 657–672 (2008).

18. A.R. Das et al., J. Surf. Sci. Technol. 14 (1–4), 41–47 (1998).

19. M.G. Neumann, C.C. Schmitt, and E.T. Iamazaki, Carbohydr. Res. 338 (10), 1109–1113 (2003).

20. T. Yoshimura, A. Ohno, and K. Esumi, J. Colloid Interface Sci. 272 (1), 191–196 (2004).

21. V.A.d.O. Tiera, M.J. Tiera, and M.G. Neumann, J. Dispers. Sci. Technol. 22 (2 & 3), 177–184 (2001).

22. M.S. Bakshi et al., J. Colloid Interface Sci. 286 (1), 369–377 (2005).

23. P.A. Bhat, G.M. Rather, and A.A. Dar, J. Phys. Chem. B 113 (4), 997–1006 (2009).

24. L.S.C. Wan and P.F.S. Lee, Can. J. Pharm. Sci. 10 (3), 69–73 (1975).

25. M.S. Bakshi and K. Singh, J. Colloid Interface Sci. 287 (1), 288–297 (2005).

26. M.S. Bakshi et al., Colloids Surf. A Physicochem. Eng. Asp. 278 (1–3), 129–139 (2006).

27. W.G. Dai et al., Int. J. Pharm. 355 (1–2), 31–37 (2008).

Citation: When referring to this article, please cite it as "W.G. Dai, L.C. Dong, and A.A. Creasey, "Inhibiting the Precipitation of Poorly Water Soluble Drugs from Labrasol Formulations," Pharmaceutical Technology 35 (6) 50-54(2011)."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
20%
Attracting a skilled workforce
28%
Obtaining/maintaining adequate financing
12%
Regulatory compliance
40%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here